c-Met和c-Src在非小细胞肺癌中表达及其与预后的关系  

Expression of c-Met and c-Src in non-small cell lung cancer and its relationship with prognosis

作　　者：孙程[1] 谭永刚[1] 闫顺朝[1] 邹华伟[1] Sun Cheng;Tan Yonggang;Yan Shunchao;Zou Huawei(Department of Oncology,Shengjing Hospital of China Medical University,Shenyang 110022,China)

机构地区：[1]中国医科大学附属盛京医院第一肿瘤科,沈阳110022

出　　处：《中国医师进修杂志》2019年第1期31-36,共6页Chinese Journal of Postgraduates of Medicine

基　　金：国家自然科学基金(81472806).

摘　　要：目的探讨c-Met和c-Src在非小细胞肺癌(NSCLC)组织中的表达及其与临床病理特征和预后的关系。方法2011年4月至2013年1月采用免疫组织化学方法检测88例NSCLC患者组织蜡块标本中c-Met和c-Src的表达水平,分析其与临床病理特征的关系及对预后的影响。结果c-Met与c-Src在NSCLC患者肿瘤组织中表达,而在间质及正常肺组织中未见表达。NSCLC中c-Met和c-Src的表达与性别、分化程度、病理类型、T分期及TNM分期相关(P<0.05或<0.01),且c-Met表达与淋巴结转移相关(P<0.01)。c-Met和c-Src表达与年龄无关,c-Src表达与淋巴结转移无关(P>0.05)。Pearson相关性分析结果显示,肺癌组织中c-Met和c-Src表达呈正相关(r=0.662,P<0.01)。Kaplan-Meier生存曲线分析结果显示,c-Met高表达患者(51例)无病生存期(DFS)和总生存期(OS)均明显短于c-Met低表达患者(37例)[(18.08±1.34)个月比(23.76±1.79)个月和(33.63±1.95)个月比(42.24±2.68)个月],c-Src高表达患者(25例)DFS和OS均明显短于c-Src低表达患者(63例)[(16.96±2.56)个月比(21.86±1.15)个月和(27.84±2.89)个月比(40.98±1.81)个月],c-Met和c-Src均高表达患者(25例)DFS和OS明显短于c-Met和c-Src均低表达患者(37例)[(16.96±2.56)个月比(23.76±1.79)个月和(27.84±2.89)个月比(42.24±2.68)个月],差异均有统计学意义(P<0.05)。Cox多因素分析结果显示,T分期(RR=2.174,95%CI1.354~3.490,P=0.001)及c-Met和c-Src均高表达(RR=1.447,95%CI1.114~1.880,P=0.006)是影响NSCLC患者DFS的独立危险因素;病理类型(RR=0.610,95%CI0.377~0.986,P=0.044)、T分期(RR=2.215,95%CI1.357~3.616,P=0.001)及c-Met和c-Src均高表达(RR=1.979,95%CI1.455~2.692,P=0.000)是影响NSCLC患者OS的独立危险因素。结论c-Met和c-Src参与NSCLC的发生和发展,影响NSCLC患者的预后。ObjectiveTo explore the expressions of c-Met and c-Src in non-small cell lung cancer (NSCLC), and its relationship with clinical pathological characters and prognosis.MethodsThe c-Met and c-Src expressions were detected by immunohistochemistry in 88 patients with NSCLC from April 2011 to January 2013. The relationship between the expressions of c-Met and c-Src and clinical pathological features and prognosis were analyzed.ResultsThe c-Met and c-Src were all significantly expressed in NSCLC tissues, and no expression showed in interstitial and normal lung tissues. The expressions of c-Met and c-Src in patients with NSCLC were associated with sex, differentiation, pathology type, T staging and TNM staging (P<0.05 or <0.01);and the expression of c-Met was associated with lymph node metastasis (P<0.01). The expressions of c-Met and c-Src in patients with NSCLC were not associated with age, and the expression of c-Src was not associated with lymph node metastasis (P>0.05). Pearson correlation analysis result showed that the expressions of c-Met and c-Src in lung cancer tissues was positive correlation (r = 0.662, P < 0.01). Kaplan-Meier survival curve analysis result showed that the disease free survival time (DFS) and overall survival time (OS) in c-Met high expression patients (51 cases) were significantly shorter than those in c-Met low expression patients (37 cases): (18.08 ± 1.34) months vs. (23.76 ± 1.79) months and (33.63 ± 1.95) months vs. (42.24 ± 2.68) months, the DFS and OS in c-Src high expression patients (25 cases) were significantly shorter than those in c-Src low expression patients (63 cases): (16.96 ± 2.56) months vs. (21.86 ± 1.15) months and (27.84 ± 2.89) months vs. (40.98 ± 1.81) months, the DFS and OS in both c-Met and c-Src high expression patients (25 cases) were significantly shorter than those in both c-Met and c-Src low expression patients (37 cases): (16.96 ± 2.56) months vs. (23.76 ± 1.79) months and (27.84 ± 2.89) months vs. (42.24 ± 2.68) months, and there were statistical d

关 键 词：癌 非小细胞肺 原癌基因蛋白质C-MET 原癌基因蛋白质pp60(c-syc) 预后 

分 类 号：R734.2[医药卫生—肿瘤]